Regulatory approval

Published by the Health Canada. Approved

PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.

This is written in the approval document.

Citation

Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00081278.PDF. Revised August 2025. Accessed April 2026.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
HC (1) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Paclitaxel, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab, Vinorelbine

Contributions

Date Contributor Description
2024-10-30 Van Allen lab Initial access of FDA approvals